Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.3
4.8
Journals
Antibiotics
Special Issues
Synthetic and Natural Products-Based Antimicrobial and Antiparasitic Agents
share announcement

Synthetic and Natural Products-Based Antimicrobial and Antiparasitic Agents

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Novel Antimicrobial Agents".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 739

Special Issue Editor

Prof. Dr. Antonio Eduardo Miller Crotti

E-Mail Website
Guest Editor
Department of Chemistry, Faculty of Philosophy, Sciences, and Letters at Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-901, Brazil
Interests: natural products; organic synthesis; biological and pharmacological activities; mass spectrometry; structural elucidation; reaction mechanisms
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Microbial and parasites are responsible for a wide diversity of diseases in humans and animals. The need for novel antimicrobials and antiparasitic agents has emerged as the current drugs have become less efficient due to resistance development. The potential of synthetic, semi-synthetic, and natural products as alternative antimicrobial (antibacterial, antifungal, and antiviral) and antiparasitic (especially antileishmanial, anti-trypanosomal, antischistosomal, and anti-toxoplasma, but not limited to them) agents will be addressed in this Special Issue. This issue will cover the discovery and design of new synthetic and semi-synthetic compounds, as well as their mechanisms of action, and structure–activity relationship (SAR) studies. Studies on bioactive microbial and plant-derived natural products and/or their semi-synthetic derivatives, as well as essential oils and their constituents, are also welcome. Authors are invited to contribute their submissions as reviews, research papers, or communications.

Prof. Dr. Antonio Eduardo Miller Crotti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Prof. Dr. Antonio Eduardo Miller Crotti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antibacterial
  • antifungal
  • antiviral
  • Candida
  • Chagas's disease
  • essential oils
  • Helicobacter
  • Leishmania
  • Schistosoma
  • Staphylococcus
  • Streptococcus
  • Toxoplasma
  • Trypanosoma

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 884 KiB  
Article
Antimicrobial and Antibiofilm Effects of Bithionol against Mycobacterium abscessus
by Dan Cao, Xin Yuan, Xiuzhi Jiang, Tiantian Wu, Yanghui Xiang, Zhongkang Ji, Jiaying Liu, Xu Dong, Kefan Bi, Tone Tønjum, Kaijin Xu and Ying Zhang
Antibiotics 2024, 13(6), 529; https://doi.org/10.3390/antibiotics13060529 - 5 Jun 2024
Viewed by 412
Abstract
Mycobacterium abscessus (M. abscessus) is a multidrug-resistant nontuberculous mycobacterium (NTM) that is responsible for a wide spectrum of infections in humans. The lack of effective bactericidal drugs and the formation of biofilm make its clinical treatment very difficult. The FDA-approved drug [...] Read more.
Mycobacterium abscessus (M. abscessus) is a multidrug-resistant nontuberculous mycobacterium (NTM) that is responsible for a wide spectrum of infections in humans. The lack of effective bactericidal drugs and the formation of biofilm make its clinical treatment very difficult. The FDA-approved drug library containing 3048 marketed and pharmacopeial drugs or compounds was screened at 20 μM against M. abscessus type strain 19977 in 7H9 medium, and 62 hits with potential antimicrobial activity against M. abscessus were identified. Among them, bithionol, a clinically approved antiparasitic agent, showed excellent antibacterial activity and inhibited the growth of three different subtypes of M. abscessus from 0.625 μM to 2.5 μM. We confirmed the bactericidal activity of bithionol by the MBC/MIC ratio being ≤4 and the time–kill curve study and also electron microscopy study. Interestingly, it was found that at 128 μg/mL, bithionol could completely eliminate biofilms after 48h, demonstrating an outstanding antibiofilm capability compared to commonly used antibiotics. Additionally, bithionol could eliminate 99.9% of biofilm bacteria at 64 μg/mL, 99% at 32 μg/mL, and 90% at 16 μg/mL. Therefore, bithionol may be a potential candidate for the treatment of M. abscessus infections due to its significant antimicrobial and antibiofilm activities. Full article
(This article belongs to the Special Issue Synthetic and Natural Products-Based Antimicrobial and Antiparasitic Agents)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

Title: In vitro antifungal activity of Gymnemic acid on Candida Albicans
Authors: Riaan Mulde
Affiliation: 0
Abstract: Natural medicine is an emerging field and is being explored to overcome drug resistance and reduce side effects in the management of oral candidiasis. Gymnemagenin (which is also known as Gymnemic acid; GA) is a purified extract from Gymnema sylvestre known for its potency against microbial and fungal activity. The study aimed to determine the effectiveness of Gymnemic acid in the inhibition of Candida growth and hyphae development. Disc diffusion tests were carried out on the agar plates containing the prepared Candida (3 plates each week). Samples of Candida albicans were transferred using a sterile loop from underneath and at the edge of each disc (NYS, CHX, GA and DH2O), for each medicament, and transferred to bovine serum vials (n=24). This was repeated for week 2 and week 3 (n=72). There was no zone of inhibition around GA and DH20 discs, while CHX and NYS discs exhibited significantly large inhibition zones. Meanwhile, there is an increase in bud size (2-4 hours) with the highest in NYS, followed by GA and CHX. The bud size significantly decreased (p>0.05) at 4-6 hours for all medicaments. Only GA progressively decreased in bud size from 6 to 24 hours. NYS increased in bud size from 6-24 hours and CHX showed little change in bud surface area. At hour 0, hyphae length base-line readings showed no hyphal growth across all treatments. Over the 24-hour period for three weeks, GA treatment significantly reduced the hyphal growth as compared to CHX and NYS treatments (p=0.05). There were no significant differences found in the hyphal length of GA over the three weeks. GA reduced the hyphae length and bud size of Candida, but unlike NYS and CHX, did not inhibit the Candidal growth. The reduction in bud size and hyphae length may indicate that GA reduced the pathogenic potential of Candida albicans, rendering it less virulent.

Back to TopTop